Related Experiment Video

Updated: Jul 6, 2026

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal

Francesco Graziano1, Annamaria Ruzzo, Fotios Loupakis

  • 1Medical Oncology Unit, Hospital of Pesaro, Pesaro, Italy. frada@tin.it

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|March 20, 2008
PubMed
Abstract

Insights

Genetic variants in EGFR intron-1 and EGF influence cetuximab efficacy in metastatic colorectal cancer. Specific genotypes like EGFR intron-1 S/S and EGF 61 G/G are linked to improved overall survival and treatment response.

Area of Science:

  • Oncology
  • Pharmacogenomics
  • Molecular Biology

Background:

  • Epidermal growth factor receptor (EGFR) signaling is crucial for cetuximab therapy effectiveness in metastatic colorectal cancer (MCRC).
  • Genetic variations in pathways regulating EGFR may impact patient outcomes.
  • Cetuximab-irinotecan salvage therapy is used after initial treatment failures.

Purpose of the Study:

  • To investigate the association between genetic polymorphisms and clinical outcomes in MCRC patients receiving cetuximab-irinotecan salvage therapy.
  • To identify genetic markers that predict overall survival (OS), treatment response, and toxicity.
  • To explore correlations between polymorphisms, EGFR expression, and clinical endpoints.

Main Methods:

  • Analysis of polymorphisms in EGF, EGFR, cyclin-D1, and Fcγ receptors in 110 MCRC patients.
  • Patients received salvage therapy after first- and second-line chemotherapy.
  • Primary endpoint was overall survival; secondary endpoints included response and toxicity.

Main Results:

  • EGFR intron-1 S/S and EGF 61 G/G genotypes were significantly associated with favorable overall survival (OS).
  • Multivariate analysis confirmed these associations, showing reduced hazard ratios for OS.
  • EGFR intron-1 S/S carriers exhibited higher rates of skin toxicity and treatment response.

Conclusions:

  • Specific genetic variants, particularly EGFR intron-1 S/S and EGF 61 G/G, may predict better outcomes with cetuximab-irinotecan therapy in MCRC.
  • These findings could aid in optimizing cetuximab treatment selection for MCRC patients.
  • Further research is needed to validate these pharmacogenomic associations.

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...